Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disorder characterized by persistent airflow limitation and chronic inflammation of the airways. According to the Centers for Disease Control and Prevention (CDC), COPD is one of the top 10 causes of death in the United States, affecting nearly 16 million U.S. adults, with many additional cases remaining undiagnosed. As per CDC chronic disease indicators, the high disease burden is driven by long-term smoking exposure, aging populations, and environmental risk factors. The chronic obstructive pulmonary disease (COPD) pipeline analysis by Expert Market Research indicates a focus on long-acting bronchodilators, combination inhaled therapies, anti-inflammatory agents, biologics targeting eosinophilic inflammation, regenerative approaches, and digital inhaler technologies. There is an increasing emphasis on improving symptom control, reducing exacerbations, and addressing unmet needs in severe and treatment-resistant patient populations.
-
Major companies involved in the chronic obstructive pulmonary disease (COPD) pipeline analysis include AstraZeneca, GlaxoSmithKline, and others.
-
Leading drugs currently in the pipeline include Tozorakimab, AZD6793, and others.
-
COPD growth is driven by smoking, air pollution, aging populations, urbanization, better diagnosis, recurrent infections, genetic risk, comorbidities, and improved patient survival.
Report Coverage
The Chronic Obstructive Pulmonary Disease (COPD) Pipeline Analysis Report by Expert Market Research gives comprehensive insights into chronic obstructive pulmonary disease (COPD) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for chronic obstructive pulmonary disease (COPD). The chronic obstructive pulmonary disease (COPD) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The chronic obstructive pulmonary disease (COPD) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with chronic obstructive pulmonary disease (COPD) treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to chronic obstructive pulmonary disease (COPD).
Read more about this report - Request a Free Sample
Chronic Obstructive Pulmonary Disease (COPD) Pipeline Outlook
Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disorder characterized by persistent airflow limitation, chronic inflammation, and recurrent exacerbations, largely driven by smoking exposure, air pollution, aging populations, and long-term occupational hazards, resulting in significant morbidity and mortality worldwide.
Chronic obstructive pulmonary disease treatment focuses on symptom control, exacerbation prevention, and slowing disease progression through bronchodilators, inhaled corticosteroids, and targeted biologic therapies. In September 2024, the treatment landscape advanced with the US Food and Drug Administration approval of dupilumab (Dupixent) for COPD patients with an eosinophilic phenotype, marking the first biologic therapy approved for this subgroup and highlighting the growing shift toward precision, inflammation-targeted treatment approaches in COPD management.
Chronic Obstructive Pulmonary Disease (COPD) Epidemiology
The COPD pipeline continues to progress as expanding epidemiological evidence highlights the growing global disease burden. According to the CDC, COPD affects nearly 16 million adults in the United States, making it one of the top 10 causes of death nationally. In Australia, official data from the Australian Institute of Health and Welfare report a prevalence of approximately 2.5% of the population, representing over 630,000 individuals living with COPD. A large-scale systematic review published on PubMed Central estimates COPD prevalence in India at around 7% among adults aged 30 years and above, reflecting substantial underdiagnosis in the population. Collectively, these prevalence trends underscore the sustained unmet clinical need and continue to support investment in novel therapeutic development and late-stage clinical programs for COPD.
Chronic Obstructive Pulmonary Disease (COPD)– Pipeline Therapeutic Assessment
This section of the report covers the analysis of chronic obstructive pulmonary disease (COPD) drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The chronic obstructive pulmonary disease (COPD) pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Peptides
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Chronic Obstructive Pulmonary Disease (COPD) Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 10%, covers a major share of the total chronic obstructive pulmonary disease (COPD) clinical trials. It is followed by Phase III at 8% and other phases.
Chronic Obstructive Pulmonary Disease (COPD) Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the chronic obstructive pulmonary disease (COPD) pipeline analysis include small molecules, monoclonal antibodies, and peptides. The chronic obstructive pulmonary disease (COPD) report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for chronic obstructive pulmonary disease (COPD). For example, lunsekimig, a novel bispecific Nanobody VHH molecule, is designed to simultaneously target interleukin-13 and thymic stromal lymphopoietin, aiming to reduce type-2 airway inflammation and eosinophilic activity in COPD, reflecting the growing focus on biologics that address upstream and downstream inflammatory pathways.
Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials – Key Players
The EMR report for the chronic obstructive pulmonary disease (COPD) pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed chronic obstructive pulmonary disease (COPD) therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in chronic obstructive pulmonary disease (COPD) clinical trials:
- AstraZeneca
- Hoffmann-La Roche
- Nuvaira, Inc.
- Sanofi
- GlaxoSmithKline
- Haisco Pharmaceutical Group Co., Ltd.
- Areteia Therapeutics
- Verona Pharma plc
- Upstream Bio Inc.
- S-INFINITY Pharmaceuticals Co., Ltd.
- Bambusa Therapeutics
- Rise Therapeutics LLC
Chronic Obstructive Pulmonary Disease (COPD) – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for chronic obstructive pulmonary disease (COPD). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of chronic obstructive pulmonary Disease (COPD) drug candidates.
Drug: AZD6793
AZD6793 is an investigational oral small-molecule therapy being developed by AstraZeneca for the treatment of chronic obstructive pulmonary disease (COPD). As highlighted on AstraZeneca’s official scientific disclosure titled “AZD6793, a novel IRAK4 inhibitor, targets multiple disease-relevant pathways in pre-clinical models of Chronic Obstructive Pulmonary Disease,” the drug works by selectively inhibiting interleukin-1 receptor-associated kinase 4 (IRAK4), a central mediator of innate immune and inflammatory signaling implicated in COPD pathophysiology. By targeting IRAK4, AZD6793 is designed to modulate multiple inflammatory pathways associated with airway inflammation, tissue damage, and disease exacerbations. The therapy is currently being evaluated in a Phase II interventional clinical trial in patients with moderate to very severe COPD to assess its efficacy, safety, and tolerability compared with placebo, with the study expected to conclude in November 2027.
Drug: Tozorakimab
Tozorakimab is an investigational anti IL 33 human monoclonal antibody being developed by AstraZeneca for the treatment of chronic obstructive pulmonary disease (COPD). According to AstraZeneca’s clinical development information, this Phase III study is evaluating the efficacy and safety of subcutaneously administered tozorakimab at two dose levels compared with placebo in adults with symptomatic COPD and a history of exacerbations, with an estimated study completion in March 2026. Tozorakimab works by targeting and inhibiting interleukin 33 signalling, a cytokine implicated in chronic inflammation and airway remodelling, thereby potentially reducing downstream pro inflammatory pathways and COPD exacerbations, as highlighted in company-reported mechanistic data on IL 33 blockade in inflammatory respiratory diseases. The trial is assessing clinical outcomes including symptom improvement, exacerbation frequency, and safety in participants receiving the antibody versus placebo.
Drug: Lunsekimig
Lunsekimig is a novel Nanobody VHH therapy being developed by Sanofi, which is sponsoring this Phase 3 interventional study for the treatment of inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. The study is evaluating the efficacy, safety, and tolerability of lunsekimig compared with placebo in adult participants with symptomatic COPD. It combines interleukin-13, a downstream cytokine associated with tissue and organ damage in respiratory diseases, and thymic stromal lymphopoietin, an upstream initiator of inflammation. Pre-clinical research suggests that simultaneous inhibition of these two pathways may provide additive and synergistic benefits in immune-mediated respiratory diseases. Lunsekimig is currently under clinical investigation, and its safety and efficacy have not yet been evaluated by any regulatory authority.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Chronic Obstructive Pulmonary Disease (COPD) Pipeline Insight Report
- Which companies/institutions are leading the chronic obstructive pulmonary disease (COPD) drug development?
- What is the efficacy and safety profile of chronic obstructive pulmonary disease (COPD) pipeline drugs?
- Which company is leading the chronic obstructive pulmonary disease (COPD) pipeline development activities?
- What is the current chronic obstructive pulmonary disease (COPD) commercial assessment?
- What are the opportunities and challenges present in the chronic obstructive pulmonary disease (COPD) pipeline landscape?
- Which company is conducting major trials for chronic obstructive pulmonary disease (COPD) drugs?
- Which companies/institutions are involved in chronic obstructive pulmonary disease (COPD) collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in chronic obstructive pulmonary disease (COPD)?
Reasons To Buy This Report
The Chronic Obstructive Pulmonary Disease (COPD) Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for chronic obstructive pulmonary disease (COPD). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into chronic obstructive pulmonary disease (COPD) collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Chronic Obstructive Pulmonary Disease (COPD) Market
Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share